Glen Harbor Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Glen Harbor Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$21K	Hold	2,816	–	–	﹤0.01%	1296
2019 Q2	$26K	Hold	2,816	–	–	﹤0.01%	1288
2019 Q1	$15K	Sell	2,816 -550	-16%	-$3.14K	﹤0.01%	1286
2018 Q4	$15K	Buy	+3,366	New	+$18.5K	﹤0.01%	1253
2018 Q3	–	Sell	-37,444	Closed	-$263K	–	1293
2018 Q2	$263K	Buy	37,444 +1,870	+5%	+$18.3K	0.01%	883
2018 Q1	$506K	Hold	35,574	–	–	0.01%	634
2017 Q4	$312K	Sell	35,574 -3,938	-10%	-$39K	0.01%	815
2017 Q3	$462K	Buy	39,512 +2,486	+7%	+$30.5K	0.01%	619
2017 Q2	$517K	Buy	37,026 +14,696	+66%	+$168K	0.01%	588
2017 Q1	$306K	Hold	22,330	–	–	0.01%	661
2016 Q4	$160K	Buy	+22,330	New	+$245K	﹤0.01%	754

Other funds holding SNDX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Glen Harbor Capital Management's SNDX Position: Q3 2019 in Review

Glen Harbor Capital Management held its Syndax Pharmaceuticals (SNDX) position steady in Q3 2019 at 2,816 shares worth $21K. The position accounts for ﹤0.01% of the portfolio, ranked #1296.

Glen Harbor Capital Management first reported a position in SNDX in Q4 2016 and has held it in 11 quarters since. The position peaked at $517K in Q2 2017. 72 funds tracked by Wall St. Rank hold SNDX as of Q3 2019.

Glen Harbor Capital Management held 2,816 shares of Syndax Pharmaceuticals worth $21K as of Q3 2019.
Glen Harbor Capital Management left its Syndax Pharmaceuticals share count unchanged in Q3 2019.
Syndax Pharmaceuticals made up ﹤0.01% of Glen Harbor Capital Management's portfolio in Q3 2019, its #1296 holding.
Glen Harbor Capital Management first reported a position in Syndax Pharmaceuticals in Q4 2016 and has held it in 11 quarters since.
Glen Harbor Capital Management's Syndax Pharmaceuticals position peaked at $517K in Q2 2017.
72 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2019.

Based on Glen Harbor Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.